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LETTER TO THE EDITOR
Journal  of  the College of  Physicians and Surgeons Pakistan 2020,  Vol.  30 (Supplement 1 COVID-19):S88S88
Convalescent Plasma: Promise
for COVID-19 Pandemic
Sir,
Severe  acute  respiratory  syndrome  coronavirus  (SAR-CoV-2),
which is the cause of coronavirus disease (COVID-19) pandemic,
challenged  scientific  minds  to  search  for  new  treatments.
Suggested therapies are in rapid development with questionable
efficacy. We proposed that human convalescent plasma is a viable
option for prevention and treatment of COVID-19, where antibody
will be given to a susceptible person as passive antibody therapy;
and  transferred  immunoglobulin  can  confer  protection  from
weeks to months. It has been used for Ebola virus outbreak in 2014
and  Middle-east  respiratory  syndrome  coronavirus  in  2015,1
SARS-CoV,  H5N1  avian  influenza,  and  H1N1  influenza.  Many
patients received single dose infusion in the past with remarkable
improvement.  Limited  data  from  China,  using  convalescent
plasma for COVID19 pandemic, has shown clinical benefit.2 Four
patients with COVID-19 received convalescent plasma, including
a pregnant woman, and recovered; however, larger studies are
required  to  investigate  the  efficacy  of  convalescent  plas-
ma therapy.3
A case series from JAMA suggested drastic improvement in clinical
parameters.4  One of the explanations was that antibodies will
suppress viremia and limit infection rate. Five critically ill patients
with COVID-19 were treated with anti SARS-CoV-2 antibodies and
found  with  negative  viral  load.  It  was  also  suggested  to  give
plasma in the early stages of  disease.  Limited published data
showed no adverse events; hence, making it more worthy treat-
ment option.
US  Federal  Drug  Authority  (FDA)  announced  a  programme,
which will be operated in collaboration with the American Red
Cross and the National Blood Banking Community in the United
States.5 This programme will provide access to investigational
convalescent plasma for patients across the nation in acute care
facilities  infected  with  SARS-CoV-2,  the  virus  that  causes
COVID-19,  exhibiting  severe  or  life-threatening  COVID-19;  or
those at high risk of progression to severe or life-threatening
disease. The convalescent plasma access programmes, led by
national initiative of physicians and investigators from 40 institu-
tions in the United States, have self-organised to investigate the
use of convalescent plasma in the current COVID-19 pandemic.
These institutions are seeking to establish a national convales-
cent plasma programme to modify the course of disease. Plasma
obtained from those who have recovered from COVID-19 will be
given to the affected ones in a hope that they will recover faster. It
is  suggested  as  one  of  the  treatments  that  scientists  could
propose. Protocols are under development. Safety data collec-
tion is under consideration to include serious adverse events,
related to administration of convalescent plasma. Patients will
be best matched with data gathering including demographics,
hospital stay, and survival to discharge. This approach will have
the potential to protect populations and will give a way forward to
study other investigational therapies.
We  anticipate  that  recovered  patients  from  COVID-19  will  be
assessed clinically, including viral nucleic acid screening. Neces-
sary regulatory permissions should be in place. Donated sera will
be pooled and used to treat individuals with early symptoms. If it is
established, it could allow many healthcare workers to maintain
their critical function. It could be used as a stopgap option amidst
pandemic. However, it is needed to pace up the efforts by authori-
ties to protect high risk individuals and consider its urgent prepara-
tion and the emergent use.
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